These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2325266)

  • 1. [In vitro induction of cytotoxic activity against carcinomatous pleural or peritoneal lymphoid cells cultivated with cytokines, and an immunological phenotypic analysis of the effector cells].
    Ebihara T; Koyama S
    Gan No Rinsho; 1990 Apr; 36(5):604-10. PubMed ID: 2325266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional and phenotypic characteristics of effusion-associated lymphoid cells cultured in the presence of either recombinant interleukin 2 or T-cell growth factor from malignant pleural and peritoneal effusions in patients with advanced carcinoma.
    Ebihara T; Koyama S
    Tohoku J Exp Med; 1990 Sep; 162(1):49-63. PubMed ID: 2077678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
    Blanchard DK; Kavanagh JJ; Sinkovics JG; Cavanagh D; Hewitt SM; Djeu JY
    Cancer Res; 1988 Nov; 48(22):6321-7. PubMed ID: 2972357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interleukin-2-activated intracavitary lymphocytes: phenotypic characteristics and effector function.
    Umiel T; Monselise J; Klein T; Rakovsky E; Fenig E; Lurie H; Adler A
    J Biol Response Mod; 1989 Aug; 8(4):409-21. PubMed ID: 2787838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
    Itoh K; Shiiba K; Ebina N; Anzai R; Ouchi A; Matsuno S
    Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma.
    Ebihara T; Fukao K; Koyama S
    Cancer; 1990 Sep; 66(5):923-9. PubMed ID: 2167147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro experimental expansion and induction of LAK cell of lymphocytes from human carcinomatous ascites].
    Li DJ
    Zhonghua Zhong Liu Za Zhi; 1989 Nov; 11(6):433-6. PubMed ID: 2634542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
    Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
    Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major histocompatibility complex-unrestricted cytolytic activity of human T cells. Analysis of precursor frequency and effector phenotype.
    Patel SS; Thiele DL; Lipsky PE
    J Immunol; 1987 Dec; 139(11):3886-95. PubMed ID: 3500232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.